Subgroup analyses based on molecular subtypes of breast tumors showed that high CDYL2b expression was significantly associated with better RFS in patients with luminal A, luminal B, and basal-like tumors but not in HER2-positive ones (Figure S8C). Here, ERBB2 is linked to breast neoplasm.